Glucovance® is a fixed-dose combination therapy containing two anti-hyperglycemic compounds, metformin hydrochloride and glibenclamide. It is indicated for the treatment of type 2 diabetes in adults, as replacement for previous combination therapy with metformin and glibenclamide in patients whose glycaemia is stable and well-controlled.1 The advanced tablet technology of Glucovance® improves glibenclamide absorption,2,3 and provides greater reduction of HbA1c than the free combination of glibenclamide and metformin, especially in more severe hyperglycemia.4